Evogene Ltd.

Investor Presentation • Jan 22, 2018

Evogene's Ag-Biologicals Division

Microbiome driving crop productivity Introduction

Ido Dor, EVP & GM, Ag-Biologicals Jan 2018

Confidential

Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

AGENDA

'Evogene Inside' – introduction to Evogene

Evogene's Ag-Biologicals Division

Summary

Evogene at a Glance

Computational Predictive Biology (CPB) Platform - applied to identify:

• Genetic elements for improved seeds
• Chemical compounds for innovative Ag-Chemicals
• Microbes for novel Ag-Biologicals
• Strategic collaborations with world-leading agriculture companies including BASF, DuPont, Monsanto, Syngenta, ICL
• Revenue model - based on licensing agreements, which typically include three main revenue streams:
  • R&D payments short term
  • Milestone payments mid term
  • Royalties from product sales longer term

Subsidiaries -

• Evofuel (100%) Castor Seeds
• Biomica (90%) Human Microbiome
• Financial fundamentals -
  • Cash position \$76 million (September 30th , 2017), no debt
  • Listed on TASE (2007) and NASDAQ (2013)

Computational Predictive Biology (CPB) Platform

Predictive Analysis and Development System

7

Corporate Structure

AGENDA

'Evogene Inside' – introduction to Evogene

Evogene's Ag-Biologicals Division

• Ag-Biologicals Market
• Vision & Strategy
• Technology
• Pipeline & Collaborations

Summary

Need for innovation

• Increasing resistance
• Regulation pressure
• Decline in product introductions

Green and Safe

• Awareness, regulations and practices

Time To Market

• Shorter time and lower cost compared to alternatives –

Ag-Biologicals - a new pillar in agriculture productivity Seeds & Traits Ag-Chemicals Fertilizers Ag-Biologicals ~\$40B ~\$50B ~\$100B

Ag-Biologicals

Products derived of natural sources

or fungi

Bio-Stimulants

Mediating plants' response to optimize yield potential

Bio-Pesticides

Support the plant by reducing pest damage to the plant

Fast growing sector with potential to complement Ag-Inputs market

Industry Recognition of the Microbiome Opportunity

Major Ag companies – actively invest in order to build position

Emerging startups – significant investments in recent 2-3 years

The Microbiome Opportunity

Billions of Microbes Matter!

Microbiome is driving crop's productivity

AGENDA

'Evogene Inside' – introduction to Evogene

Evogene's Ag-Biologicals Division

• Ag-Biologicals Market
• Vision & Strategy
• Technology
• Pipeline & Collaborations

Summary

Increasing crop's productivity through productive microbiome

To introduce environmentally safe and effective microbiome based Ag-Biological products driving crop's productivity

Addressing Key Challenges

Addressing key challenges of :

efficacy, stability and commercial viability

Position on Value Chain

• Short time to market
• End to end capabilities for product development

Product Offering

Evogene's Ag-Biologicals Product Strategy

Balance between Row and Specialty crops & direct vs.

Balanced product programs: Bio-stimulants and Biopesticides

Enabling Fermentation & Formulation technology driving product stability and efficay

Leverage of core program for extension into new product types

Cost effective application paths

Position on Value Chain

Model A – Indirect Market Access

• Focus mainly on row crops
• Go-to-market based on partners channel

Model B – Direct Market Access

• Focus mainly on high value specialty

crops

• Commercialization through distributors / strategic licensing agreements

AGENDA

'Evogene Inside' – introduction to Evogene

Evogene's Ag-Biologicals Division

• Ag-Biologicals Market
• Vision & Strategy

Technology

Pipeline & Collaborations

Summary

Decoding complex plant - pest - microbiome interaction for the identification of genetic elements with desired features for the development of microbial based products

Utilizing a proprietary Computational Predictive Biology (CPB) Platform harnessing the power of genotypic & phenotypic BIG DATA through advanced informatics

Products

CPB Platform to Support Product Development

Utilizing a proprietary Computational Predictive Biology (CPB) platform harnessing the power of genotypic & phenotypic BIG DATA through advanced informatics

AGENDA

'Evogene Inside' – introduction to Evogene

Evogene's Ag-Biologicals Division

• Ag-Biologicals Market
• Vision & Strategy
• Technology
• Pipeline & Collaborations

Summary

Ag – Biological Product Portfolio Pipeline

nts a ul m Sti o- Bi	1	Corn
	2	Wheat
es d ectici ns o-I Bi	3	Corn Root Worm
	4	Stink -Bug - soy
	5	Lepidoptera - specialty
es d gici n u F o- Bi	6	Fusarium bio - fungicide - Corn
	7	Mildews Bio - Fungicide - grapes

10% Yield improvement in field trials (2016, 2017)

Under moderate drought

Results

18% yield increase in field (2017) EVO33394+EVO33393

13% yield increase in field (2017) EVO33394+EVO33402

Results

Bio-Insecticides examples (initial Lab, Greenhouse)

Western corn root worm 83% increase in leaf area 50% reduction in insect survival

Fall Army Warm Leaf disk assay results

EVO30013

BL

Fusarium in corn - ~70% reduction in disease severity

AGENDA

'Evogene Inside' – introduction to Evogene

Evogene's Ag-Biologicals Division

Summary

Value Creation Roadmap

1 Ag–Biologicals - fastest growing sector in Agriculture inputs, expected to reach \$8B in 2022

• 2 Ag-Biologicals time to market is relatively short due to favorable regulatory landscape
• 3 Microbiome is a promising opportunity to drive Ag-Biologicals market's expansion
• 4 Evogene's Computational Predictive Biology platform (CPB), combining biological understanding and cutting-edge computational technology is key for next generation product development

Initiated in 2015, Evogene already generated valuable product pipelines for bio-stimulants & biopesticides is in place – potential 1 st product launch in 2021

Evogene's Ag-Biologicals Division

Microbiome driving crop productivity Introduction

Ido Dor, EVP & GM, Ag-Biologicals Jan 2018

Confidential